Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
Source: SeekingAlpha
2026-03-07 09:20:50 ET
More on Incyte, Novo Nordisk, etc.
- CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry
- Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
- Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- MacroGenics drops after FDA partial clinical hold on lead program
- Novo’s China obesity drug posts positive mid-stage trial results
Read the full article on Seeking Alpha
For further details see:
Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
MacroGenics Inc.
NASDAQ: MGNX
MGNX Trading
2.25% G/L:
$4.325 Last:
255,268 Volume:
$4.19 Open:
MGNX Latest News
May 14, 2026 04:01:00 pm
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
May 13, 2026 04:01:00 pm
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MGNX Stock Data
$110,069,846
55,034,923
1.49%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
